Please login to the form below

Not currently logged in

Amgen's John Kearney to lead ABPI's pricing negotiation team

Negotiators will also include GSK's Erik van Snippenberg and Pfizer's Jon Emms

The ABPI has unveiled the team of pharmaceutical executives that will represent the UK industry when pricing negotiations with the Department of Health formally begin.

The industry and DH will sit down next month to begin working out details of the UK's next pricing scheme, which will replace the current Prescription Pricing and Reimbursement Scheme (PPRS).

Heading up the ABPI's negotiating side will be team chair John Kearney, who is UK and Ireland general manager at biopharmaceutical company Amgen.

Serving with him will be GSK's UK general manager Erik van Snippenberg, Pfizer's UK managing director Jon Emms, UCB's British and Irish Isles managing director Matthew Speers and Alliance's executive director Pete Butterfield.

Keen to stress the inclusive nature of its team, the ABPI said it was representative of different sized companies as well as the different geographies within the UK industry.

The UK industry body will also provide a team of its own to support the pharma negotiators and this will be led by ABPI commercial director Alison Clough.

It is currently proposed that from 2014 a value-based pricing (VBP) system, incorporating a broader assessment of a product's worth, will be used to determine prices for medicines that are newly launched onto the UK market, while an updated version of the PPRS will be used to decide the price of branded drugs already available.

10th August 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Helen Lawn and Associates

Established in 2000, Helen Lawn and Associates has gained widespread industry recognition as a trusted, UK-based healthcare PR agency....

Latest intelligence

Pharma Marketing Summit: From ”why” to ”how” in multichannel communications
For the first time we’re sharing our observations of pharma conferences — kicking off with our delegates’ views of the Annual Pharma Marketing Summit in Berlin last month....
Access to orphan drugs for rare cancers in EU28
Revisiting Instagram for pharma
In pharma, Instagram usage is increasing because it offers so many benefits to engage with patients and HCPs...